Carnegie acted as joint global co-ordinator in the rights issue of 2.7 million new shares, with pre-emptive rights to existing shareholders, bringing the company gross proceeds of DKK 771 million. The subscription price was DKK 280 with a margin to TERP at launch of approx. 26 per cent. The offering was structured as a public offering in Denmark and the United Kingdom and as a private placement in other jurisdictions. NeuroSearch A/S is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. November, 2007.